- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04968106
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) (TORNADO)
March 2, 2023 updated by: Institut Bergonié
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial.
Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B.
Study Type
Interventional
Enrollment (Anticipated)
66
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bordeaux, France, 33076
- Recruiting
- Institut Bergonie
-
Lyon, France
- Recruiting
- Centre LEON BERARD
-
Contact:
- Mehdi BRAHMI, MD
- Email: mehdi.brahmi@lyon.unicancer.fr
-
Paris, France
- Not yet recruiting
- Institut Curie
-
Villejuif, France, 94805
- Withdrawn
- Institut Gustave Roussy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with grade 2 or grade 3 soft-tissue sarcoma (limb, trunk wall, retroperitoneum) histologically confirmed and reviewed by the RRePS Network
- For TLS status determination: available archived FFPE tumor tissue sample.
- Presence of mature tertiary lymphoid structures. Except if presence of TLS have been already confirmed by Biopathological platform at Bergonié Institute, presence of TLS should be confirmed by central review based on FFPE tumor tissue sample (archived or newly obtained by biopsy for research purpose).
- Non-metastatic and resectable disease,
- At least one lesion that can be biopsied for research purpose,
- No prior treatment for the disease under study,
- Age ≥ 18 years,
- ECOG ≤ 1,
- Life expectancy > 3 months,
- Patients must have measurable disease defined as per RECIST v1.1
- Adequate hematological, renal, metabolic and hepatic function
- Left ventricular ejection fraction ≥ 50% assessed by ECHO or MUGA within 6 months from study entry,
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry. .
- Both women and men must agree to use a highly effective method of contraception throughout the treatment period and for one year after discontinuation of treatment for women and 4 months for men.
- No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, concomitant endometrial carcinoma stage IA grade 1, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
- Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5),
- Voluntarily signed and dated written informed consent prior to any study specific procedure,
- Patients with a social security in compliance with the French law.
Exclusion Criteria:
- Previous treatment for retroperitoneal sarcoma including surgery, chemotherapy or radiotherapy
- Previous treatments with doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines or anthracenediones at the maximum cumulative dose,
- Known hypersensitivity to any involved study drug or any of its formulation components,
- Has an active or ongoing infection requiring systemic therapy,
- Known central nervous system malignancy (CNS),
- Women who are pregnant or breast feeding,
- Has known active hepatitis B or hepatitis C,
- Has a known history of Human Immunodeficiency Virus (HIV),
- Previous enrolment in the present study,
- Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
- Has received a live attenuated vaccine or a live vaccine within 30 days prior to the first dose of trial treatment, Note: the killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:
- Myocardial infarction or stroke/transient ischemic attack within the 6 months prior to study entry.
- Uncontrolled angina within the 3 months prior to study entry.
- Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes, or poorly controlled atrial fibrillation).
- Corrected QT (QTc) prolongation > 480 msec.
- History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled venous thrombus).
Uncontrolled or significant renal disease including, but not limited to, any of the following:
- Acute or uncontrolled urinary infection at study entry,
- Hemorrhagic cystitis at study entry,
- Presence of blood on dipstick at study entry,
- Vesical atony,
- Known urinary tract obstruction.
- Patients with known history of active inflammatory bowel diseases, including those with small or large intestine inflammation, such as Crohn's disease or ulcerative colitis, will be excluded from the study,
- Has received systemic antibiotics within 14 days before the first dose of study treatment. Participants receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.
- History of organ transplant, including allogeneic stem cell transplantation.
- Receiving probiotics as of the first dose of study treatment.
Has an active autoimmune disease
- Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible,
- Patients requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at dose ≤ 10 mg or 10 mg equivalent prednisone day,
- Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intra-ocular, intra-articular or inhalation) are acceptable.
- Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis.
- Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment. Note: Participants must have recovered from all radiation-related toxicities (to Grade >1 or baseline), not require corticosteroids for this purpose, and not have had radiation pneumonitis.
- Person under judicial protection or deprived of liberty.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard Arm A: treatment by neoadjuvant chemotherapy
Treatment by doxorubicin and ifosfamide followed by surgery
|
Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
|
Experimental: Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab
Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
|
Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide)
Time Frame: 5 months after treatment onset
|
Antitumor activity will be assessed in terms of histological response based on surgical sample
|
5 months after treatment onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year progression-free survival
Time Frame: 1 year
|
Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
|
1 year
|
3-year progression-free survival
Time Frame: 3 years
|
Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
|
3 years
|
1-year overall survival
Time Frame: 1 year
|
Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).
|
1 year
|
3-year overall survival
Time Frame: 3 years
|
Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).
|
3 years
|
Safety profile independently for each arm: Common Terminology Criteria for Adverse event version 5
Time Frame: Throughout the treatment period, an expected average of 6 months
|
Toxicity will be grade using the Common Terminology Criteria for adverse events version 5 and coded according to the standardized medical terminology MedDRA
|
Throughout the treatment period, an expected average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2022
Primary Completion (Anticipated)
March 1, 2025
Study Completion (Anticipated)
October 1, 2027
Study Registration Dates
First Submitted
July 13, 2021
First Submitted That Met QC Criteria
July 13, 2021
First Posted (Actual)
July 20, 2021
Study Record Updates
Last Update Posted (Estimate)
March 3, 2023
Last Update Submitted That Met QC Criteria
March 2, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Ifosfamide
- Doxorubicin
Other Study ID Numbers
- IB 2021-01
- 2021-001085-37 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resectable Sarcoma
-
Institut BergoniéNovartis; Chugai Pharma FranceRecruitingResectable | Non-metastatic Soft-tissue SarcomaFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Not yet recruitingMetastatic Sarcoma | Resectable Sarcoma | Recurrent SarcomaUnited States
-
Centre Leon BerardRecruitingSoft Tissue Sarcoma | Resectable Soft Tissue Sarcoma | Adult Soft Tissue SarcomaFrance
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingSoft Tissue Sarcoma | Recurrent Soft Tissue Sarcoma | Resectable Soft Tissue SarcomaUnited States
-
Ain Shams UniversityActive, not recruitingResectable Soft Tissue Sarcoma | Extremities | Radiotherapy Wound ComplicationsEgypt
-
Roswell Park Cancer InstituteRecruitingColorectal Cancer | Metastatic Unresectable Sarcoma | Metastatic Malignant Neoplasm in the Lung | Resectable Sarcoma | Metastatic Soft Tissue Sarcoma | Metastatic Bone SarcomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingSoft Tissue Sarcoma | Resectable Soft Tissue SarcomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Resectable Soft Tissue Sarcoma | Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IB Soft Tissue Sarcoma of the Trunk and Extremities...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight TherapeuticsActive, not recruitingLeiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Myxofibrosarcoma | Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the... and other conditionsUnited States
-
Peking University People's HospitalPeking University Shougang HospitalCompletedPulmonary Disease | Osteosarcoma Metastatic | Survival | Resectable SarcomaChina
Clinical Trials on Doxorubicin
-
Azaya Therapeutics, Inc.UnknownCancer | Ovarian Cancer | Ovarian Epithelial Cancer Recurrent | Malignant Female Reproductive System Neoplasm | Ovarian TumorCanada, United States
-
National Cancer Institute (NCI)CompletedDS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...United States
-
OnxeoCompletedCarcinoma, HepatocellularItaly, Spain, United States, Belgium, Austria, France, Egypt, Germany, Hungary, Turkey, Lebanon
-
Sohag UniversityActive, not recruiting
-
AEterna ZentarisCompletedEndometrial CancerUnited States, Spain, Canada, Ireland, Norway, Austria, Denmark, Israel, United Kingdom, Belgium, Finland, Romania, Czechia, Italy, Poland, Germany, Netherlands, Belarus, Bosnia and Herzegovina, Bulgaria, Russian Federation, Ukraine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Falo, Louis, MDActive, not recruitingCutaneous T Cell LymphomaUnited States
-
SOLTI Breast Cancer Research GroupCompleted
-
Yale UniversityCompleted